EGFR and head and neck squamous cell carcinoma: However, although preclinical data support the co-targeting of EGFR and Met in these tumors (117), according to the recently published results of a phase II trial performed in patients with recurrent/metastatic HNSCC, the combination between Cetuximab and the Met inhibitor Tivantinib did not improve response rates or patients survival compared with Cetuximab alone, while it was associated with increased toxicities (118–120).